TY - JOUR
T1 - MACSima imaging cyclic staining (MICS) technology reveals combinatorial target pairs for CAR T cell treatment of solid tumors
AU - Kinkhabwala, Ali
AU - Herbel, Christoph
AU - Pankratz, Jennifer
AU - Yushchenko, Dmytro A.
AU - Rüberg, Silvia
AU - Praveen, Paurush
AU - Reiß, Sandy
AU - Rodriguez, Federico Carlos
AU - Schäfer, Daniel
AU - Kollet, Jutta
AU - Dittmer, Vera
AU - Martinez-Osuna, Manuel
AU - Minnerup, Lara
AU - Reinhard, Claudia
AU - Dzionek, Andrzej
AU - Rockel, Thomas Dino
AU - Borbe, Stefan
AU - Büscher, Martin
AU - Krieg, Jürgen
AU - Nederlof, Michel
AU - Jungblut, Melanie
AU - Eckardt, Dominik
AU - Hardt, Olaf
AU - Dose, Christian
AU - Schumann, Eik
AU - Peters, Ralf-Peter
AU - Miltenyi, Stefan
AU - Schmitz, Jürgen
AU - Muller, Werner
AU - Bosio, Andreas
PY - 2022/2/3
Y1 - 2022/2/3
N2 - Many critical advances in research utilize techniques that combine high-resolution with high-content characterization at the single cell level. We introduce the MICS (MACSima Imaging Cyclic Staining) technology, which enables the immunofluorescent imaging of hundreds of protein targets across a single specimen at subcellular resolution. MICS is based on cycles of staining, imaging, and erasure, using photobleaching of fluorescent labels of recombinant antibodies (REAfinity Antibodies), or release of antibodies (REAlease Antibodies) or their labels (REAdye_lease Antibodies). Multimarker analysis can identify potential targets for immune therapy against solid tumors. With MICS we analysed human glioblastoma, ovarian and pancreatic carcinoma, and 16 healthy tissues, identifying the pair EPCAM/THY1 as a potential target for chimeric antigen receptor (CAR) T cell therapy for ovarian carcinoma. Using an Adapter CAR T cell approach, we show selective killing of cells only if both markers are expressed. MICS represents a new high-content microscopy methodology widely applicable for personalized medicine.
AB - Many critical advances in research utilize techniques that combine high-resolution with high-content characterization at the single cell level. We introduce the MICS (MACSima Imaging Cyclic Staining) technology, which enables the immunofluorescent imaging of hundreds of protein targets across a single specimen at subcellular resolution. MICS is based on cycles of staining, imaging, and erasure, using photobleaching of fluorescent labels of recombinant antibodies (REAfinity Antibodies), or release of antibodies (REAlease Antibodies) or their labels (REAdye_lease Antibodies). Multimarker analysis can identify potential targets for immune therapy against solid tumors. With MICS we analysed human glioblastoma, ovarian and pancreatic carcinoma, and 16 healthy tissues, identifying the pair EPCAM/THY1 as a potential target for chimeric antigen receptor (CAR) T cell therapy for ovarian carcinoma. Using an Adapter CAR T cell approach, we show selective killing of cells only if both markers are expressed. MICS represents a new high-content microscopy methodology widely applicable for personalized medicine.
U2 - 10.1038/s41598-022-05841-4
DO - 10.1038/s41598-022-05841-4
M3 - Article
SN - 2045-2322
VL - 12
JO - Scientific Reports
JF - Scientific Reports
M1 - 1911
ER -
